Drugs / Glucagon-Like Peptide 1
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04355832 | Jun 2020 → Sep 2025 | type 1 diabetes mellitus | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02129179 | Jun 2014 → Dec 2016 | heart failure | Papworth Hospital NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00609154 | Aug 2010 → May 2014 | type 2 diabetes mellitus | Albert Einstein College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT00798590 | Dec 2008 → Jun 2010 | hypoglycemia | Johns Hopkins University | Terminated | No outcome recorded |
| Phase not applicable3 trials · 1 met primary | ||||||
| — | NCT00612950 | Oct 2006 → Feb 2007 | type 2 diabetes mellitus | Hvidovre University Hospital | Completed | Met primary |
| — | NCT00256256 | Nov 2005 → Jan 2007 | myocardial infarction, stroke disorder, type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT00612625 | Feb → Jul 2004 | type 2 diabetes mellitus | Hvidovre University Hospital | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 0 | NCT01858896 Comparator | Jul 2013 → Sep 2026 overdue | type 2 diabetes mellitus | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
| — | NCT04337268 Comparator | Apr 2019 → Mar 2020 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| — | NCT03081676 Comparator | Mar 2017 → Jun 2018 | maturity-onset diabetes of the young type 3 | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT01413542 Comparator | Nov 2011 → Jul 2013 | hypertensive disorder, type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00923962 Comparator | Jun 2009 → Jan 2012 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT00418288 Comparator | Jan → Oct 2007 | myocardial infarction, stroke disorder, type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
Press releases naming this drug 4 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glucagon like peptide-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923962 ↗ |
| Known as | GLP-1 | “The naturally occurring hormone GLP-1 when co-administered during hypoglycemia (low blood sugar) in non-diabetic individuals can reduce the deleterious effects of hypoglycemia...” NCT04355832 ↗3“The ability of glucagon-like peptide-1 (GLP-1) to enhance beta cell responsiveness to i.v. glucose is impaired in patients with type 2 diabetes mellitus compared with healthy...” PMID 18292985 ↗ Feb 2008 “Glucagon-like peptide-1 (GLP-1) may provide beneficial cardiovascular effects, possibly due to enhanced myocardial energetic efficiency by increasing myocardial glucose uptake (MGU).” PMID 24400077 ↗ Jan 2014 “The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells.” NCT00609154 ↗ |
| Action | Activate | “GLP-1 receptor stimulation” NCT00923962 ↗ |
| Modality | Peptide | “glucagon-like peptide-1” NCT00612950 ↗ |
| Route | Other | “continuous infusion of GLP-1” NCT00612625 ↗ |